ramucirumab (Cyramza)
Jump to navigation
Jump to search
Indications
- advanced gastric cancer
- gastroesophageal junction adenocarcinoma
- for use in patients with unresectable gastric cancer or metastatic gastric cancer after treatment with fluoropyrimidine- (5-fluoruracil) or platinum-containing (cisplatin) therapy
- may be used in combination with paclitaxel (Taxol)
- in combination with FOLFIRI (after ramucirumab) for treatment of metastatic colorectal cancer[2]
- metastatic non-small cell lung cancer in combination with docetaxel
- disease progression on or after platinum-based chemotherapy
- disease progression on erlotinib or crizotinib[3][4]
* improves median survival 5.2 vs 3.8 months with placebo
Benefit/risk
- overall survival with ramucirumab versus placebo (13.3 vs 11.7 months) for metastatic colorectal cancer[2]
Adverse effects
Mechanism of action
- angiogenesis inhibitor
- directly targets the VEGF receptor 2 (VEGFR2) via ligand- binding site[2]
- blocks the blood supply to tumor
More general terms
- pharmaceutical angiogenesis inhibitor (angiostatic agent)
- antineoplastic agent (chemotherapeutic agent)
References
- ↑ Kelly KJ FDA Approves Drug to Treat Advanced Stomach Cancer. Physician's First Watch, April 23, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release: April 21, 2014 FDA approves Cyramza for stomach cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394107.htm - ↑ 2.0 2.1 2.2 2.3 Tabernero J et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015 May; 16:499 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25877855 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970127-0/abstract
- ↑ 3.0 3.1 Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24933332
- ↑ 4.0 4.1 Perol M, Ciuleanu TE, Arrieta O et al Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo- plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer. 2016 Mar;93:95-103. Epub 2016 Jan 19. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26898621